INTRODUCTION: We examined patient outcomes after Gamma Knife stereotactic radiosurgery (GKSRS) salvage therapy for recurrent high-grade gliomas (HGGs) to determine whether tumor grade or lesion size affected overall survival (OS) and progression-free survival (PFS). METHODS: This single-center retrospective study assessed radiographic response and clinical outcomes following GKSRS salvage treatment of recurrent malignant gliomas (January 2005-March 2014). RESULTS: A total of 121 patients (67 female) with 132 tumors were treated. Median (range) PFS was 4.7 (3.9-5.4) months for the cohort, 6.8 (4.6-8.9) months for initial grade 2 tumors, 4.2 (1.9-6.5) months for initial grade 3 tumors, and 4.3 (3.7-4.9) months for initial grade 4 tumors. Patients with small lesions (≤6.7 cm3; n = 53) had significantly longer median (range) PFS (6.8 [4.8-8.8], P=0.02). CONCLUSIONS: GKSRS offers meaningful salvage therapy with minimal morbidity in appropriately selected patients with focally recurrent HGGs.
INTRODUCTION: We examined patient outcomes after Gamma Knife stereotactic radiosurgery (GKSRS) salvage therapy for recurrent high-grade gliomas (HGGs) to determine whether tumor grade or lesion size affected overall survival (OS) and progression-free survival (PFS). METHODS: This single-center retrospective study assessed radiographic response and clinical outcomes following GKSRS salvage treatment of recurrent malignant gliomas (January 2005-March 2014). RESULTS: A total of 121 patients (67 female) with 132 tumors were treated. Median (range) PFS was 4.7 (3.9-5.4) months for the cohort, 6.8 (4.6-8.9) months for initial grade 2 tumors, 4.2 (1.9-6.5) months for initial grade 3 tumors, and 4.3 (3.7-4.9) months for initial grade 4 tumors. Patients with small lesions (≤6.7 cm3; n = 53) had significantly longer median (range) PFS (6.8 [4.8-8.8], P=0.02). CONCLUSIONS: GKSRS offers meaningful salvage therapy with minimal morbidity in appropriately selected patients with focally recurrent HGGs.
Authors: R S Hudes; B W Corn; M Werner-Wasik; D Andrews; J Rosenstock; L Thoron; B Downes; W J Curran Journal: Int J Radiat Oncol Biol Phys Date: 1999-01-15 Impact factor: 7.038
Authors: Thomas Hundsberger; Detlef Brügge; Paul M Putora; Patrik Weder; Johannes Weber; Ludwig Plasswilm Journal: J Neurooncol Date: 2013-01-12 Impact factor: 4.130
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Erik W Larson; Halloran E Peterson; Wayne T Lamoreaux; Alexander R MacKay; Robert K Fairbanks; Jason A Call; Jonathan D Carlson; Benjamin C Ling; John J Demakas; Barton S Cooke; Christopher M Lee Journal: World J Clin Oncol Date: 2014-05-10
Authors: Nader Pouratian; R Webster Crowley; Jonathan H Sherman; Jay Jagannathan; Jason P Sheehan Journal: J Neurooncol Date: 2009-03-29 Impact factor: 4.130
Authors: Anudeep Yekula; Abigail Taylor; Alexandra Beecroft; Keiko M Kang; Julia L Small; Koushik Muralidharan; Zachary Rosh; Bob S Carter; Leonora Balaj Journal: Cancer Drug Resist Date: 2021-03-19